AU2005249502A1 - Particulate-stabilized injectable pharmaceutical compositions of posaconazole - Google Patents

Particulate-stabilized injectable pharmaceutical compositions of posaconazole Download PDF

Info

Publication number
AU2005249502A1
AU2005249502A1 AU2005249502A AU2005249502A AU2005249502A1 AU 2005249502 A1 AU2005249502 A1 AU 2005249502A1 AU 2005249502 A AU2005249502 A AU 2005249502A AU 2005249502 A AU2005249502 A AU 2005249502A AU 2005249502 A1 AU2005249502 A1 AU 2005249502A1
Authority
AU
Australia
Prior art keywords
formulation
posaconazole
mean
plasma
hour
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005249502A
Other languages
English (en)
Inventor
Catherine Hardalo
Roberta S. Hare
Gopal Krishna
Varda Sandweiss
Marco Taglietti
Sydney Ugwu
Zaiqi Wang
Leonore Witchey-Lakshmanan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2005249502(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU2005249502A1 publication Critical patent/AU2005249502A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2005249502A 2004-05-28 2005-05-27 Particulate-stabilized injectable pharmaceutical compositions of posaconazole Abandoned AU2005249502A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57512604P 2004-05-28 2004-05-28
US60/575,126 2004-05-28
PCT/US2005/018945 WO2005117831A1 (en) 2004-05-28 2005-05-27 Injectable pharmaceutical suspension comprising posaconazole

Publications (1)

Publication Number Publication Date
AU2005249502A1 true AU2005249502A1 (en) 2005-12-15

Family

ID=34971355

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005249502A Abandoned AU2005249502A1 (en) 2004-05-28 2005-05-27 Particulate-stabilized injectable pharmaceutical compositions of posaconazole

Country Status (15)

Country Link
EP (1) EP1761247A1 (https=)
JP (1) JP2008501034A (https=)
KR (1) KR20070027564A (https=)
CN (1) CN1988887A (https=)
AR (1) AR049063A1 (https=)
AU (1) AU2005249502A1 (https=)
CA (1) CA2567803A1 (https=)
IL (1) IL179627A0 (https=)
MX (1) MXPA06013886A (https=)
NO (1) NO20066005L (https=)
PE (1) PE20060291A1 (https=)
RU (1) RU2006146555A (https=)
TW (1) TWI290051B (https=)
WO (1) WO2005117831A1 (https=)
ZA (1) ZA200609890B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060009469A1 (en) * 2004-05-28 2006-01-12 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmacutical compositions of posaconazole
EP2018164B1 (de) 2006-05-12 2017-03-01 Christian Noe Verwendung von kombinationspräparaten, umfassend antimykotika
EP2130540A1 (en) * 2008-06-02 2009-12-09 Sandoz AG Pharmaceutical compositions containing a crystalline form of posaconazole
EP2141159A1 (en) 2008-07-03 2010-01-06 Sandoz AG A Crystalline form of posaconazole
WO2011003992A1 (en) 2009-07-09 2011-01-13 Sandoz Ag A crystalline form of posaconazole
CN102906087B (zh) 2010-05-19 2016-03-23 桑多斯股份公司 制备手性三唑酮的方法
JP5955837B2 (ja) 2010-05-19 2016-07-20 サンド・アクチエンゲゼルシヤフト ポサコナゾール及びポサコナゾール中間体の精製
EP2571847B1 (en) 2010-05-19 2016-09-21 Sandoz AG Process for the preparation of chiral hydrazides
AU2011254657B2 (en) 2010-05-19 2016-02-04 Sandoz Ag Preparation of posaconazole intermediates
HUE056581T2 (hu) 2010-06-29 2022-02-28 Merck Sharp & Dohme Szubsztituált béta-ciklodextrinnel stabilizált pozakonazol intravénás oldat formulációk
CA2838051C (en) 2011-06-16 2019-09-24 Sandoz Ag Process for the preparation of a chiral compound
CN103284959B (zh) * 2012-02-22 2015-06-03 重庆圣华曦药业股份有限公司 泊沙康唑冻干粉针剂及制备方法
CN102755628B (zh) * 2012-07-16 2013-10-23 中国科学院微生物研究所 一种抗真菌的药物组合物
CN102805731B (zh) * 2012-08-22 2014-04-30 北京莱瑞森医药科技有限公司 泊沙康唑干混悬剂及其制备方法
CN105030668B (zh) * 2015-06-26 2018-03-27 济川药业集团有限公司 泊沙康唑口服混悬剂及其制备方法
CN106333925B (zh) * 2015-07-10 2019-06-18 上海美悦生物科技发展有限公司 一种泊沙康唑液体混悬剂及其制备方法
CN105997872B (zh) * 2016-07-08 2019-02-19 河南省立眼科医院 一种含有泊沙康唑的眼用纳米胶束抗真菌溶液
CN110582264B (zh) * 2017-03-26 2022-11-11 V·R·斯塔福德 眼睑皮肤状况的处理方法
CN111093373A (zh) * 2017-04-12 2020-05-01 V·J·班格万丁 组合物、包装的药物和使用泊沙康唑用于敏化抗性肿瘤的方法
CN110507609B (zh) * 2018-05-21 2021-09-17 上海医药工业研究院 泊沙康唑口服混悬剂的制备方法
CN111514146A (zh) * 2020-04-28 2020-08-11 山西振东泰盛制药有限公司 含有泊沙康唑的药物组合物
CN113933131B (zh) * 2021-09-24 2024-01-26 合肥天一生物技术研究所有限责任公司 一种阴道微生物荧光染色液

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
EP1372394A1 (en) * 2001-04-03 2004-01-02 Schering Corporation Antifungal composition with enhanced bioavailability

Also Published As

Publication number Publication date
CN1988887A (zh) 2007-06-27
TWI290051B (en) 2007-11-21
RU2006146555A (ru) 2008-07-20
WO2005117831A1 (en) 2005-12-15
PE20060291A1 (es) 2006-04-14
MXPA06013886A (es) 2007-01-26
ZA200609890B (en) 2008-09-25
EP1761247A1 (en) 2007-03-14
KR20070027564A (ko) 2007-03-09
IL179627A0 (en) 2007-05-15
NO20066005L (no) 2007-02-27
JP2008501034A (ja) 2008-01-17
CA2567803A1 (en) 2005-12-15
AR049063A1 (es) 2006-06-21
TW200609001A (en) 2006-03-16

Similar Documents

Publication Publication Date Title
AU2005249502A1 (en) Particulate-stabilized injectable pharmaceutical compositions of posaconazole
US20090226527A1 (en) Particulate-stabilized injectable pharmacutical compositions of posaconazole
US8414904B2 (en) Ophthalmic oil-in-water emulsions containing prostaglandins
TWI556838B (zh) 治療關節炎之方法
US11110169B2 (en) Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
EP3049104B1 (en) Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20060009469A1 (en) Particulate-stabilized injectable pharmacutical compositions of posaconazole
AU2016400406A1 (en) Viscoelastic gel of liraglutide adapted for once-weekly or once bi-weekly administration
JP2024116313A (ja) 真菌感染症を処置するための化合物および方法
KR20140046395A (ko) 경구 투여를 위한 선택적 인자 ｘａ 억제제의 제약 조성물
US20220031625A1 (en) Ophthalmic compositions for delivering meibum-like materials
CN107126418B (zh) 供注射用双氯芬酸钠药物组合物及其制备方法
US20030206929A1 (en) Amphotercin b structured emulsion
JP2024528195A (ja) ブラジキニンｂ２受容体拮抗薬を経口投与するための脂質ベースの組成物
US20240299378A1 (en) Emulsion for use in the treatment of rosacea
CN107811969B (zh) 一种高稳定性的非囊泡型纳米颗粒及其在治疗真菌感染中的应用
OA20177A (en) Compounds and methods for treating fungal infections.
EA045995B1 (ru) Соединения и способы лечения грибковых инфекций
Leigh Phospholipids as Carriers for Vaginal Drug Delivery
EA037435B1 (ru) Фармацевтическая композиция, содержащая бензидамин
HK1133598B (en) Ophthalmic oil-in-water emulsions containing prostaglandins

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ PARTICULATE-STABILIZED INJECTABLEPHARMACEUTICAL COMPOSITIONS OF POSACONAZOLE

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted